SEPTInvestingStart Free

ENTX 8-K: SEC filing

Entera Bio

Filed with the SEC on · accession 0001178913-26-005056

ENTX filed a 8-K (current report) with the SEC on Nov 6, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved +5.0% by the first close after the filing.

Summary of the filing

Entera Bio reported Q3 2026 financial results with cash of $265.9M following a $275M private placement, and provided business updates including Phase 3 EB613 osteoporosis study preparations, executive and board appointments, and ongoing EB612 development with OPKO.

For details, click here →How to read a 8-K →

Key details

Cash and cash equivalents as of September 30, 2026$265.9M
Restricted cash$6.5M
Gross proceeds from oversubscribed private placement$275.0M
R&D expenses for Q3 2026$4.9M
R&D expenses for Q3 2025$1.6M
IssuerEntera Bio Ltd.
Collaboration partner for eb612OPKO Health
Lead investor in private placementBVF Partners L.P.
InvestorLongitude Capital
InvestorVivo Capital
InvestorTCGX
InvestorSpruce Street Capital
InvestorVenrock Healthcare Capital Partners
InvestorRA Capital Management
InvestorPerceptive Advisors
InvestorDriehaus Capital Management
InvestorLogos Capital
InvestorCatalio Capital Management
Chief executive officerMiranda Toledano
Chief medical officerRiccardo Paolo Camisasca
Senior vice president, medical affairsMichele McDermott
Vice president and head of early clinical developmentOfer Spiegelstein
Vice president, clinical development and study leadGraziella Soulban
Board directorLaura Hamill
Board directorJuan Camilo Arjona Ferreira

How ENTX stock reacted

Close before

$2.99

Nov 5, 2026

First close after

+5.02%

$3.14

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ENTX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ENTX?

Click here

Frequently asked questions

What did ENTX file with the SEC on Nov 6, 2026?

ENTX filed a 8-K (SEC filing). Entera Bio reported Q3 2026 financial results with cash of $265.9M following a $275M private placement, and provided business updates including Phase 3 EB613 osteoporosis study preparations, executive and board appointments, and ongoing EB612 development with OPKO.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did ENTX stock react to this filing?

ENTX closed at $2.99 before the filing and $3.14 on Nov 6, 2026 (+5.02%).

Other ENTX SEC filings

Get alerts when ENTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ENTX overviewENTX analysisENTX newsLatest SEC filings